Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Canada / NCT03217786
Active, not recruiting Observational

Early Post Transplant Cardiac Allograft Vasculopathy

NCT03217786 · tracked via the Priya Life Science Canada tracker
Sponsor
Ottawa Heart Institute Research Corporation
Phase
Observational
Started
2018-02-12
Last updated
2026-04-30

Condition(s) studied

Cardiac Allograft Vasculopathy

Study summary

Heart transplantation is an effective life-saving treatment for patients with end-stage heart disease. After a transplant, the new heart may develop narrowing in the arteries, causing heart failure, heart attacks and abnormal heart rhythms. This condition is known as cardiac allograft vasculopathy (CAV). The disease is very common, affecting almost a third of heart transplant patients by 5 years after transplant. CAV is a serious problem that causes the new heart to fail and is one of the main causes of death after transplant. Early detection of CAV is important as treatment options are poor once the disease is established. Currently, available techniques to evaluate CAV are limited by poor ability to detect disease early. The current tests usually focus on the large heart arteries and do not examine the smaller arteries that are also affected.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Heart transplant \<3 months. 2. Age ≥18 years. 3. Able and willing to provide informed consent. Exclusion Criteria: 1. Contraindications to dipyridamole. 2. Contraindications to aminophylline. 3. Contraindications to nitroglycerin. 4. Contraindications to iodinated contrast. 5. Acute allograft rejection ≤1 month. 6. Uncontrolled heart failure or myocardial infarction ≤7 days. 7. Estimated glomerular filtration rate ≤30 mL/min. 8. Combined solid organ transplantation.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Ottawa Heart Institute Ottawa Ontario

More Ottawa Heart Institute Research Corporation trials in Canada

Comparing Hypothermic Temperatures During Hemiarch Surgery Recruiting
Hemiarch vs Extended Arch in Type 1 Aortic Dissection Recruiting
AERIAL Trial: Antiplatelet Therapy in Heart Transplantation Recruiting
Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED) Recruiting
Feasibility of High-Intensity Interval Nordic Walking in Patients With Coronary Artery Disease Active, not recruiting

Other trials for the same condition

AERIAL Trial: Antiplatelet Therapy in Heart Transplantation Recruiting
MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03217786 on ClinicalTrials.gov ↗ ← All trials in Canada